For Immediate Release
Chicago, IL – August 21, 2012 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include ConocoPhillips (COP - Analyst Report) , Transocean Ltd. (RIG - Analyst Report) , Exxon Mobil Corporation (XOM - Analyst Report) , Chevron Corporation (CVX - Analyst Report) and Genomic Health (GHDX - Analyst Report) .
Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: https://at.zacks.com/?id=5513
Here are highlights from Monday’s Analyst Blog:
Conoco Resumes Work in Poseidon
Oil and gas explorer ConocoPhillips (COP - Analyst Report) has finally resumed drilling operations in the Greater Poseidon area, off Western Australia.
The field was being spud by Transocean Ltd.’s (RIG - Analyst Report) semi-submersible rig Transocean Legend. ConocoPhillips had to halt operations in late May – consequent to the drilling of the Boreas-1 exploration well in WA-314-P – because a blowout preventer (BOP) was required to be repaired.
The repair work took two and a half months. According to the project partner, Karoon Gas Australia Ltd., various efforts to repair were ineffective. However, the BOP is fully serviceable and spudding has restarted.
Located about 2.4 miles (4 kilometers) south of the Poseidon-1 gas discovery in WA-315-P on a large tilted fault block, Boreas-1 is among the first of a minimum five exploration wells in the Greater Poseidon area. The block forms part of the northeast leaning structural high of the greater Poseidon structure.
ConocoPhillips and Karoon have jointly discovered Poseidon-1, Poseidon-2 and Kronos-1 in the area. In order to support a liquefied natural gas project, they are targeting to build reserves.
ConocoPhillips retains the operatorship of the jointly held WA-314-P, WA-315-P and WA-398-P Browse Basin permits, which comprise the earlier announced Poseidon and Kronos gas discoveries. Karoon has a 40% stake in the WA-315-P and WA-398-P permits and 90% in WA-314-P.
ConocoPhillips’ exploration initiatives toward liquids-rich plays are gaining momentum through the Eagle Ford, Bakken and North Barnett shale plays. ConocoPhillips has separated its downstream business to unlock value, unlike its peer companies –– Exxon Mobil Corporation (XOM - Analyst Report) and Chevron Corporation (CVX - Analyst Report) , which continue to operate as single units.
However, the company faces greater challenges than its larger peers in generating attractive growth, given its above-average exposure to the mature regions. Again, though Conoco is one of the largest natural gas companies in North America, it lacks material exposure to the prolific non-conventional plays.
We maintain an Underperform recommendation on ConocoPhillips for the long term.
Genomic Health Back to Neutral
Genomic Health (GHDX - Analyst Report) reported mixed second quarter 2012 results with earnings per share of 6 cents that were well above the Zacks Consensus Estimates for a loss of 2 cents, but revenues of $57.6 million that missed.
While we are impressed with Genomic Health’s progress with respect to its Oncotype franchise, additional investments are being made to fund its newly formed subsidiary, InVitae Corporation. The company recorded a net loss of $800,000 related to InVitae during the quarter, which is adversely affecting its bottom line.
In addition, margin continues to remain under pressure as operating expenses have been increasing over the past few quarters and are likely to increase in the second half of 2012. This will primarily be due to Genomic Health’s investment in the core cancer business with new recruitments, initiation of new studies and groundwork preparation for the prospective launch of a prostate cancer test. As a result, we prefer to go back to our Neutral recommendation as upside potential of the stock seems limited.
While the company currently has two products in its portfolio, Oncotype DX breast and Oncotype DX colon cancer tests, the second one is yet to make any significant contribution to the top line. Penetration of the colon cancer test could improve gradually with Genomic Health’s efforts on securing reimbursement and the rise in patient base with the inclusion of stage III patients being treated with oxaliplatin-containing adjuvant therapy.
The company has come a long way from being a one-product U.S. focused company in 2007, when 24,450 tests were delivered (with a 22% penetration), to the present when more than 66,000 Oncotype DX test results (with 16% growth) were delivered in 2011. Genomic Health also diversified its offering with the launch of the Oncotype DX DCIS Score at the end of 2011.
The company recorded 16% year-over-year growth in test volume to 19,020 tests during the reported quarter on the back of deeper penetration in new markets – DCIS, colon cancer and international. It has been observed that the Oncotype DX breast cancer test changed treatment decision in 37% of the early-stage breast cancer patients resulting in hundreds of millions of dollars in healthcare savings. Besides, we are encouraged with the progress made by the company on the reimbursement front.
Having established a strong foothold in the U.S. market, Genomic Health is targeting the international arena and is entering into several agreements to meet this objective. The company’s Oncotype DX breast and colon cancer tests are available to patients in 86 and 75 countries, respectively through these collaborations. Securing reimbursement outside the U.S. continues to be the major driver of growth in the international business.
Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter: https://at.zacks.com/?id=5515.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today: https://at.zacks.com/?id=5517
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leon Zacks. As a PhD from MIT Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at https://at.zacks.com/?id=5518.
Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Follow us on Twitter: http://twitter.com/zacksresearch
Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.
Zacks Investment Research
800-767-3771 ext. 9339